ID   IL6_MOUSE               Reviewed;         211 AA.
AC   P08505; Q3UCQ0; Q8BN26;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   07-APR-2021, entry version 190.
DE   RecName: Full=Interleukin-6 {ECO:0000305};
DE            Short=IL-6;
DE   AltName: Full=B-cell hybridoma growth factor;
DE   AltName: Full=Interleukin HP-1;
DE   Flags: Precursor;
GN   Name=Il6 {ECO:0000312|MGI:MGI:96559}; Synonyms=Il-6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2965020; DOI=10.1002/eji.1830180202;
RA   van Snick J., Cayphas S., Szikora J.-P., Renauld J.-C., van Roost E.,
RA   Boon T., Simpson R.J.;
RT   "cDNA cloning of murine interleukin-HP1: homology with human interleukin
RT   6.";
RL   Eur. J. Immunol. 18:193-197(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3263439;
RA   Tanabe O., Akira S., Kamiya T., Wong G.G., Hirano T., Kishimoto T.;
RT   "Genomic structure of the murine IL-6 gene. High degree conservation of
RT   potential regulatory sequences between mouse and human.";
RL   J. Immunol. 141:3875-3881(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3262872; DOI=10.1073/pnas.85.19.7099;
RA   Chiu C.P., Moulds C., Coffman R.L., Rennick D., Lee F.;
RT   "Multiple biological activities are expressed by a mouse interleukin 6 cDNA
RT   clone isolated from bone marrow stromal cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7099-7103(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ;
RX   PubMed=2243807; DOI=10.1093/nar/18.21.6455;
RA   Grenett H.E., Fuentes N.L., Fuller G.M.;
RT   "Cloning and sequence analysis of the cDNA for murine interleukin-6.";
RL   Nucleic Acids Res. 18:6455-6455(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Macrophage;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RC   STRAIN=BALB/cJ;
RX   PubMed=2106569; DOI=10.1084/jem.171.3.965;
RA   Blankenstein T., Qin Z., Li W., Diamantstein T.;
RT   "DNA rearrangement and constitutive expression of the interleukin 6 gene in
RT   a mouse plasmacytoma.";
RL   J. Exp. Med. 171:965-970(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-211.
RC   STRAIN=C57BL/6J;
RX   PubMed=2563387;
RA   Mock B.A., Nordan R.P., Justice M.J., Kozak C., Jenkins N.A.,
RA   Copeland N.G., Clark S.C., Wong G.G., Rudikoff S.;
RT   "The murine Il-6 gene maps to the proximal region of chromosome 5.";
RL   J. Immunol. 142:1372-1376(1989).
RN   [8]
RP   PROTEIN SEQUENCE OF 25-45.
RX   PubMed=2948184; DOI=10.1073/pnas.83.24.9679;
RA   van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie P.G., Rubira M.R.,
RA   Simpson R.J.;
RT   "Purification and NH2-terminal amino acid sequence of a T-cell-derived
RT   lymphokine with growth factor activity for B-cell hybridomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9679-9683(1986).
RN   [9]
RP   PROTEIN SEQUENCE OF 25-211.
RX   PubMed=3262059; DOI=10.1111/j.1432-1033.1988.tb14267.x;
RA   Simpson R.J., Moritz R.L., Rubira M.R., van Snick J.;
RT   "Murine hybridoma/plasmacytoma growth factor. Complete amino-acid sequence
RT   and relation to human interleukin-6.";
RL   Eur. J. Biochem. 176:187-197(1988).
RN   [10]
RP   PROTEIN SEQUENCE OF 66-75; 78-84 AND 128-148.
RX   PubMed=2302197; DOI=10.1016/0006-291x(90)91922-f;
RA   Jahnen W., Ward L.D., Reid G.E., Moritz R.L., Simpson R.J.;
RT   "Internal amino acid sequencing of proteins by in situ cyanogen bromide
RT   cleavage in polyacrylamide gels.";
RL   Biochem. Biophys. Res. Commun. 166:139-145(1990).
RN   [11]
RP   DISULFIDE BONDS.
RX   PubMed=3264160; DOI=10.1016/s0006-291x(88)80056-1;
RA   Simpson R.J., Moritz R.L., van Roost E., van Snick J.;
RT   "Characterization of a recombinant murine interleukin-6: assignment of
RT   disulphide bonds.";
RL   Biochem. Biophys. Res. Commun. 157:364-372(1988).
RN   [12]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=8910279; DOI=10.1126/science.274.5291.1379;
RA   Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E.,
RA   Poli V., Taub R.;
RT   "Liver failure and defective hepatocyte regeneration in interleukin-6-
RT   deficient mice.";
RL   Science 274:1379-1383(1996).
RN   [13]
RP   FUNCTION.
RX   PubMed=11113088; DOI=10.1053/gast.2000.20236;
RA   Peters M., Blinn G., Jostock T., Schirmacher P.,
RA   Meyer zum Bueschenfelde K.H., Galle P.R., Rose-John S.;
RT   "Combined interleukin 6 and soluble interleukin 6 receptor accelerates
RT   murine liver regeneration.";
RL   Gastroenterology 119:1663-1671(2000).
RN   [14]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=11786910; DOI=10.1038/nm0102-75;
RA   Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H.,
RA   Dickson S.L., Ohlsson C., Jansson J.O.;
RT   "Interleukin-6-deficient mice develop mature-onset obesity.";
RL   Nat. Med. 8:75-79(2002).
RN   [15]
RP   FUNCTION.
RX   PubMed=15124018; DOI=10.1172/jci200420945;
RA   Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K.,
RA   Ganz T.;
RT   "IL-6 mediates hypoferremia of inflammation by inducing the synthesis of
RT   the iron regulatory hormone hepcidin.";
RL   J. Clin. Invest. 113:1271-1276(2004).
RN   [16]
RP   FUNCTION.
RX   PubMed=17075861; DOI=10.1002/art.22175;
RA   De Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M.,
RA   Vivarelli M., Muratori F., Berni S., Ballanti P., Ferrari S., Teti A.;
RT   "Impaired skeletal development in interleukin-6-transgenic mice: a model
RT   for the impact of chronic inflammation on the growing skeletal system.";
RL   Arthritis Rheum. 54:3551-3563(2006).
RN   [17]
RP   FUNCTION IN TH17 DIFFERENTIATION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16990136; DOI=10.1016/j.cell.2006.07.035;
RA   Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A.,
RA   Lafaille J.J., Cua D.J., Littman D.R.;
RT   "The orphan nuclear receptor RORgammat directs the differentiation program
RT   of proinflammatory IL-17+ T helper cells.";
RL   Cell 126:1121-1133(2006).
RN   [18]
RP   FUNCTION, AND INDUCTION BY EXERCISE.
RX   PubMed=22037645; DOI=10.1038/nm.2513;
RA   Ellingsgaard H., Hauselmann I., Schuler B., Habib A.M., Baggio L.L.,
RA   Meier D.T., Eppler E., Bouzakri K., Wueest S., Muller Y.D., Hansen A.M.,
RA   Reinecke M., Konrad D., Gassmann M., Reimann F., Halban P.A., Gromada J.,
RA   Drucker D.J., Gribble F.M., Ehses J.A., Donath M.Y.;
RT   "Interleukin-6 enhances insulin secretion by increasing glucagon-like
RT   peptide-1 secretion from L cells and alpha cells.";
RL   Nat. Med. 17:1481-1489(2011).
RN   [19]
RP   FUNCTION, DISRUPTION PHENOTYPE, TISSUE SPECIFICITY, AND INDUCTION BY VIRAL
RP   INFECTION.
RX   PubMed=23045607; DOI=10.1084/jem.20111504;
RA   Karnowski A., Chevrier S., Belz G.T., Mount A., Emslie D., D'Costa K.,
RA   Tarlinton D.M., Kallies A., Corcoran L.M.;
RT   "B and T cells collaborate in antiviral responses via IL-6, IL-21, and
RT   transcriptional activator and coactivator, Oct2 and OBF-1.";
RL   J. Exp. Med. 209:2049-2064(2012).
RN   [20]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=28402851; DOI=10.1016/j.celrep.2017.03.043;
RA   Timper K., Denson J.L., Steculorum S.M., Heilinger C., Engstroem-Ruud L.,
RA   Wunderlich C.M., Rose-John S., Wunderlich F.T., Bruening J.C.;
RT   "IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced
RT   Central IL-6 trans-Signaling.";
RL   Cell Rep. 19:267-280(2017).
RN   [21]
RP   INTERACTION WITH SORL1.
RX   PubMed=28265003; DOI=10.1128/mcb.00641-16;
RA   Larsen J.V., Petersen C.M.;
RT   "SorLA in Interleukin-6 Signaling and Turnover.";
RL   Mol. Cell. Biol. 37:0-0(2017).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=27893700; DOI=10.1038/ni.3632;
RA   Heink S., Yogev N., Garbers C., Herwerth M., Aly L., Gasperi C.,
RA   Husterer V., Croxford A.L., Moeller-Hackbarth K., Bartsch H.S., Sotlar K.,
RA   Krebs S., Regen T., Blum H., Hemmer B., Misgeld T., Wunderlich T.F.,
RA   Hidalgo J., Oukka M., Rose-John S., Schmidt-Supprian M., Waisman A.,
RA   Korn T.;
RT   "Trans-presentation of IL-6 by dendritic cells is required for the priming
RT   of pathogenic TH17 cells.";
RL   Nat. Immunol. 18:74-85(2017).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=30995492; DOI=10.1016/j.immuni.2019.03.026;
RA   Kang S., Tanaka T., Narazaki M., Kishimoto T.;
RT   "Targeting Interleukin-6 Signaling in Clinic.";
RL   Immunity 50:1007-1023(2019).
CC   -!- FUNCTION: Cytokine with a wide variety of biological functions in
CC       immunity, tissue regeneration, and metabolism (Probable). Binds to
CC       IL6R, then the complex associates to the signaling subunit IL6ST/gp130
CC       to trigger the intracellular IL6-signaling pathway (PubMed:8910279).
CC       The interaction with the membrane-bound IL6R and IL6ST stimulates
CC       'classic signaling', whereas the binding of IL6 and soluble IL6R to
CC       IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling'
CC       occurs when membrane-bound IL6:IL6R complexes on transmitter cells
CC       activate IL6ST receptors on neighboring receiver cells
CC       (PubMed:27893700). {ECO:0000269|PubMed:27893700,
CC       ECO:0000269|PubMed:8910279, ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: IL6 is a potent inducer of the acute phase response. Rapid
CC       production of IL6 contributes to host defense during infection and
CC       tissue injury, but excessive IL6 synthesis is involved in disease
CC       pathology. In the innate immune response, is synthesized by myeloid
CC       cells, such as macrophages and dendritic cells, upon recognition of
CC       pathogens through toll-like receptors (TLRs) at the site of infection
CC       or tissue injury. In the adaptive immune response, is required for the
CC       differentiation of B-cells into immunoglolin-secreting cells
CC       (Probable). Plays a major role in the differentiation of CD4(+) T cell
CC       subsets. Essential factor for the development of T follicular helper
CC       (Tfh) cells that are required for the induction of germinal-center
CC       formation. Together with IL21, controls the early generation of Tfh
CC       cells and are critical for an effective antibody response to acute
CC       viral infection (PubMed:23045607). Required to drive naive CD4(+) T
CC       cells to the Th17 lineage, through 'cluster signaling' by dendritic
CC       cells (PubMed:16990136, PubMed:27893700). Also required for
CC       proliferation of myeloma cells and the survival of plasmablast cells
CC       (Probable). {ECO:0000269|PubMed:16990136, ECO:0000269|PubMed:23045607,
CC       ECO:0000269|PubMed:27893700, ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: Acts as an essential factor in bone homeostasis and on
CC       vessels directly or indirectly by induction of VEGF, resulting in
CC       increased angiogenesis activity and vascular permeability. Induces,
CC       through 'trans-signaling' and synergistically with IL1B and TNF, the
CC       production of VEGF (PubMed:17075861). Involved in metabolic controls,
CC       is discharged into the bloodstream after muscle contraction increasing
CC       lipolysis and improving insulin resistance (PubMed:11786910). 'Trans-
CC       signaling' in central nervous system regulates energy and glucose
CC       homeostasis (PubMed:28402851). Mediates, through GLP-1, crosstalk
CC       between insulin-sensitive tissues, intestinal L cells and pancreatic
CC       islets to adapt to changes in insulin demand (PubMed:11113088). Also
CC       acts as a myokine (By similarity). Plays a protective role during liver
CC       injury, being required for maintenance of tissue regeneration
CC       (PubMed:11113088, PubMed:8910279). Also has a pivotal role in iron
CC       metabolism by regulating HAMP/hepcidin expression upon inflammation or
CC       bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-
CC       NOTCH pathway, induces inflammation-induced epithelial regeneration (By
CC       similarity). {ECO:0000250|UniProtKB:P05231,
CC       ECO:0000269|PubMed:11113088, ECO:0000269|PubMed:11786910,
CC       ECO:0000269|PubMed:15124018, ECO:0000269|PubMed:17075861,
CC       ECO:0000269|PubMed:28402851, ECO:0000269|PubMed:8910279}.
CC   -!- SUBUNIT: Component of a hexamer of two molecules each of IL6, IL6R and
CC       IL6ST; first binds to IL6R to associate with the signaling subunit
CC       IL6ST (PubMed:28265003). Interacts with IL6R (via the N-terminal
CC       ectodomain); this interaction may be affected by IL6R-binding with
CC       SORL1, hence decreasing IL6 cis signaling. Interacts with SORL1 (via
CC       the N-terminal ectodomain); this interaction leads to IL6
CC       internalization and lysosomal degradation. May form a trimeric complex
CC       with the soluble SORL1 ectodomain and soluble IL6R receptor; this
CC       interaction might stabilize circulating IL6, hence promoting IL6 trans
CC       signaling (PubMed:28265003). {ECO:0000269|PubMed:28265003}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:27893700}.
CC   -!- TISSUE SPECIFICITY: Expressed by dendritic cells and macrophages
CC       (PubMed:27893700, PubMed:23045607). Expressed by activated follicular B
CC       cells (PubMed:23045607). Abundantly expressed in the central nervous
CC       system (CNS), particularly the hypothalamic region (PubMed:28402851).
CC       {ECO:0000269|PubMed:23045607, ECO:0000269|PubMed:27893700,
CC       ECO:0000269|PubMed:28402851}.
CC   -!- INDUCTION: In activated follicular B cells, expression is induced early
CC       after influenza virus infection (PubMed:23045607). Plasma levels are
CC       highly increased upon exercise, due to enhanced production by
CC       contracting skeletal muscles (PubMed:22037645).
CC       {ECO:0000269|PubMed:22037645, ECO:0000269|PubMed:23045607}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000250|UniProtKB:P05231}.
CC   -!- DISRUPTION PHENOTYPE: Animals have normal T-cell numbers in the lamina
CC       propria but the T(H)17 cells are reduced by about 10-fold
CC       (PubMed:16990136). They develop mature-onset obesity and have disturbed
CC       carbohydrate and lipid metabolism, increased leptin levels and
CC       decreased responsiveness to leptin treatment (PubMed:11786910). Animals
CC       have impaired liver regeneration characterized by liver necrosis and
CC       failure (PubMed:8910279). Mutants infected with influenza virus do not
CC       show a significant difference on germinal center B cells compared to
CC       wild-types (PubMed:23045607). Double knockouts for IL21 and IL6
CC       infected with influenza virus show a significant reduction in germinal
CC       centers in both the draining lymphatic nodes and the spleens to wild-
CC       types. Animals show a significant reduction in virus-specific IgM and
CC       IgG (PubMed:23045607). {ECO:0000269|PubMed:11786910,
CC       ECO:0000269|PubMed:16990136, ECO:0000269|PubMed:23045607,
CC       ECO:0000269|PubMed:8910279}.
CC   -!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X06203; CAA29560.1; -; mRNA.
DR   EMBL; M20572; AAA39302.1; -; Genomic_DNA.
DR   EMBL; J03783; AAA39301.1; -; mRNA.
DR   EMBL; X54542; CAA38411.1; -; mRNA.
DR   EMBL; AK150440; BAE29562.1; -; mRNA.
DR   EMBL; X51457; CAA35824.1; -; Genomic_DNA.
DR   EMBL; M24221; AAA68814.1; -; Genomic_DNA.
DR   CCDS; CCDS19153.1; -.
DR   PIR; A30531; ICMS6.
DR   RefSeq; NP_001300983.1; NM_001314054.1.
DR   RefSeq; NP_112445.1; NM_031168.2.
DR   PDB; 2L3Y; NMR; -; A=27-211.
DR   PDBsum; 2L3Y; -.
DR   SMR; P08505; -.
DR   BioGRID; 200641; 2.
DR   IntAct; P08505; 1.
DR   STRING; 10090.ENSMUSP00000026845; -.
DR   PhosphoSitePlus; P08505; -.
DR   MaxQB; P08505; -.
DR   PaxDb; P08505; -.
DR   PRIDE; P08505; -.
DR   ProteomicsDB; 267327; -.
DR   Antibodypedia; 12025; 2808 antibodies.
DR   Ensembl; ENSMUST00000026845; ENSMUSP00000026845; ENSMUSG00000025746.
DR   GeneID; 16193; -.
DR   KEGG; mmu:16193; -.
DR   UCSC; uc008wuu.1; mouse.
DR   CTD; 3569; -.
DR   MGI; MGI:96559; Il6.
DR   eggNOG; ENOG502S7Q4; Eukaryota.
DR   GeneTree; ENSGT00390000000878; -.
DR   HOGENOM; CLU_096521_0_0_1; -.
DR   InParanoid; P08505; -.
DR   OrthoDB; 1144279at2759; -.
DR   PhylomeDB; P08505; -.
DR   TreeFam; TF335984; -.
DR   Reactome; R-MMU-1059683; Interleukin-6 signaling.
DR   Reactome; R-MMU-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-MMU-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-MMU-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-MMU-8957275; Post-translational protein phosphorylation.
DR   BioGRID-ORCS; 16193; 0 hits in 54 CRISPR screens.
DR   EvolutionaryTrace; P08505; -.
DR   PRO; PR:P08505; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   RNAct; P08505; protein.
DR   Bgee; ENSMUSG00000025746; Expressed in subcutaneous adipose tissue and 56 other tissues.
DR   Genevisible; P08505; MM.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; ISO:MGI.
DR   GO; GO:0005138; F:interleukin-6 receptor binding; IDA:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:MGI.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IDA:MGI.
DR   GO; GO:0045454; P:cell redox homeostasis; ISO:MGI.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IDA:MGI.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISO:MGI.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:MGI.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI.
DR   GO; GO:0031669; P:cellular response to nutrient levels; IEA:Ensembl.
DR   GO; GO:1990646; P:cellular response to prolactin; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:MGI.
DR   GO; GO:0098586; P:cellular response to virus; IMP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0042832; P:defense response to protozoan; IMP:MGI.
DR   GO; GO:0051607; P:defense response to virus; ISO:MGI.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:BHF-UCL.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IDA:MGI.
DR   GO; GO:0010467; P:gene expression; IDA:MGI.
DR   GO; GO:0002314; P:germinal center B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0070091; P:glucagon secretion; IMP:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IDA:UniProtKB.
DR   GO; GO:0002384; P:hepatic immune response; ISO:MGI.
DR   GO; GO:0072574; P:hepatocyte proliferation; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISO:MGI.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IMP:UniProtKB.
DR   GO; GO:0031294; P:lymphocyte costimulation; IEA:Ensembl.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IGI:MGI.
DR   GO; GO:0002262; P:myeloid cell homeostasis; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0045779; P:negative regulation of bone resorption; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:MGI.
DR   GO; GO:0032682; P:negative regulation of chemokine production; IDA:MGI.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; ISO:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISO:MGI.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; ISO:MGI.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IDA:MGI.
DR   GO; GO:2000660; P:negative regulation of interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0045837; P:negative regulation of membrane potential; ISO:MGI.
DR   GO; GO:0048635; P:negative regulation of muscle organ development; ISO:MGI.
DR   GO; GO:1901215; P:negative regulation of neuron death; ISO:MGI.
DR   GO; GO:2000635; P:negative regulation of primary miRNA processing; ISO:MGI.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; ISO:MGI.
DR   GO; GO:0031175; P:neuron projection development; ISO:MGI.
DR   GO; GO:0001781; P:neutrophil apoptotic process; IDA:MGI.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; ISO:MGI.
DR   GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; ISO:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0050871; P:positive regulation of B cell activation; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:MGI.
DR   GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IGI:MGI.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:MGI.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:MGI.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; ISO:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:MGI.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; ISO:MGI.
DR   GO; GO:0014015; P:positive regulation of gliogenesis; IMP:ARUK-UCL.
DR   GO; GO:0002639; P:positive regulation of immunoglobulin production; IMP:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:MGI.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISO:MGI.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IDA:ARUK-UCL.
DR   GO; GO:0032745; P:positive regulation of interleukin-21 production; IDA:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:MGI.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISO:MGI.
DR   GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISO:MGI.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISO:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:MGI.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; ISO:MGI.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISO:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISO:MGI.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; ISO:MGI.
DR   GO; GO:1904894; P:positive regulation of receptor signaling pathway via STAT; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:MGI.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; ISO:MGI.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; IMP:BHF-UCL.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0045727; P:positive regulation of translation; ISO:MGI.
DR   GO; GO:0051971; P:positive regulation of transmission of nerve impulse; ISO:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:MGI.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISO:MGI.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; ISO:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IGI:MGI.
DR   GO; GO:0008360; P:regulation of cell shape; ISO:MGI.
DR   GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; ISO:MGI.
DR   GO; GO:0070092; P:regulation of glucagon secretion; IDA:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; IDA:UniProtKB.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; ISO:MGI.
DR   GO; GO:0014823; P:response to activity; IDA:UniProtKB.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; ISO:MGI.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IDA:MGI.
DR   GO; GO:0001878; P:response to yeast; IEA:Ensembl.
DR   GO; GO:0042110; P:T cell activation; IGI:MGI.
DR   GO; GO:0061470; P:T follicular helper cell differentiation; IMP:UniProtKB.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; IDA:UniProtKB.
DR   GO; GO:0010573; P:vascular endothelial growth factor production; ISS:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR003574; IL-6.
DR   InterPro; IPR030474; IL-6/GCSF/MGF.
DR   InterPro; IPR030473; IL6/GCSF/MGF_CS.
DR   PANTHER; PTHR10511; PTHR10511; 1.
DR   PANTHER; PTHR10511:SF3; PTHR10511:SF3; 1.
DR   Pfam; PF00489; IL6; 1.
DR   PIRSF; PIRSF001935; IL6_MGF_GCSF; 1.
DR   PRINTS; PR00433; IL6GCSFMGF.
DR   SMART; SM00126; IL6; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
DR   PROSITE; PS00254; INTERLEUKIN_6; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Cytokine; Direct protein sequencing;
KW   Disulfide bond; Growth factor; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:2948184,
FT                   ECO:0000269|PubMed:3262059"
FT   CHAIN           25..211
FT                   /note="Interleukin-6"
FT                   /id="PRO_0000015588"
FT   DISULFID        70..76
FT                   /evidence="ECO:0000269|PubMed:3264160"
FT   DISULFID        99..109
FT                   /evidence="ECO:0000269|PubMed:3264160"
FT   HELIX           48..68
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   TURN            69..72
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           74..77
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   TURN            81..83
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           84..86
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   STRAND          101..103
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           114..129
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           133..160
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           170..176
FT                   /evidence="ECO:0007744|PDB:2L3Y"
FT   HELIX           186..209
FT                   /evidence="ECO:0007744|PDB:2L3Y"
SQ   SEQUENCE   211 AA;  24384 MW;  BBB47DDA9E86787A CRC64;
     MKFLSARDFH PVAFLGLMLV TTTAFPTSQV RRGDFTEDTT PNRPVYTTSQ VGGLITHVLW
     EIVEMRKELC NGNSDCMNND DALAENNLKL PEIQRNDGCY QTGYNQEICL LKISSGLLEY
     HSYLEYMKNN LKDNKKDKAR VLQRDTETLI HIFNQEVKDL HKIVLPTPIS NALLTDKLES
     QKEWLRTKTI QFILKSLEEF LKVTLRSTRQ T
//
